Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 261

1.

Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer.

Djalalov S, Beca J, Hoch JS, Krahn M, Tsao MS, Cutz JC, Leighl NB.

J Clin Oncol. 2014 Apr 1;32(10):1012-9. doi: 10.1200/JCO.2013.53.1186. Epub 2014 Feb 24.

2.

Cost effectiveness of crizotinib for anaplastic lymphoma kinase-positive, non-small-cell lung cancer: who is going to blink at the cost?

Kelly RJ, Hillner BE, Smith TJ.

J Clin Oncol. 2014 Apr 1;32(10):983-5. doi: 10.1200/JCO.2013.54.6002. Epub 2014 Feb 24. No abstract available.

3.

The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers.

Atherly AJ, Camidge DR.

Br J Cancer. 2012 Mar 13;106(6):1100-6. doi: 10.1038/bjc.2012.60. Epub 2012 Feb 28.

4.

Targeted therapies in non-small-cell lung cancer management: no cost-effective strategies?

Chouaid C, Borget I, Vergnenegre A.

J Clin Oncol. 2014 Nov 1;32(31):3577. doi: 10.1200/JCO.2014.56.2157. Epub 2014 Sep 8. No abstract available.

5.

ALK inhibitors in the treatment of advanced NSCLC.

Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F.

Cancer Treat Rev. 2014 Mar;40(2):300-6. doi: 10.1016/j.ctrv.2013.07.002. Epub 2013 Aug 7. Review.

PMID:
23931927
6.

Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation?

Chun SG, Choe KS, Iyengar P, Yordy JS, Timmerman RD.

Cancer Biol Ther. 2012 Dec;13(14):1376-83. doi: 10.4161/cbt.22255. Epub 2012 Sep 17.

7.

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.

Katayama R, Khan TM, Benes C, Lifshits E, Ebi H, Rivera VM, Shakespeare WC, Iafrate AJ, Engelman JA, Shaw AT.

Proc Natl Acad Sci U S A. 2011 May 3;108(18):7535-40. doi: 10.1073/pnas.1019559108. Epub 2011 Apr 18.

8.

Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.

O'Bryant CL, Wenger SD, Kim M, Thompson LA.

Ann Pharmacother. 2013 Feb;47(2):189-97. doi: 10.1345/aph.1R002. Epub 2013 Feb 5. Review.

PMID:
23386065
9.

Genotyping lung cancer is an investment in the future.

Azzoli CG, Engelman J, Fidias P, Gainor JF, Heist RS, Lamont EB, Lennes IT, Rosovsky RP, Sequist LV, Shaw AT, Temel JS.

J Clin Oncol. 2014 Nov 1;32(31):3576-7. doi: 10.1200/JCO.2014.56.6430. Epub 2014 Sep 8. No abstract available.

10.

Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden.

Guérin A, Sasane M, Zhang J, Culver KW, Dea K, Nitulescu R, Wu EQ.

J Med Econ. 2015 Apr;18(4):312-22. doi: 10.3111/13696998.2014.1003644. Epub 2015 Feb 6.

PMID:
25565443
11.

ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.

Casaluce F, Sgambato A, Maione P, Rossi A, Ferrara C, Napolitano A, Palazzolo G, Ciardiello F, Gridelli C.

Target Oncol. 2013 Mar;8(1):55-67. doi: 10.1007/s11523-012-0250-9. Epub 2013 Jan 17. Review.

PMID:
23325296
12.

ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.

Scagliotti G, Stahel RA, Rosell R, Thatcher N, Soria JC.

Eur J Cancer. 2012 May;48(7):961-73. doi: 10.1016/j.ejca.2012.02.001. Epub 2012 Mar 6.

PMID:
22397764
13.

Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy.

Takeda M, Okamoto I, Sakai K, Kawakami H, Nishio K, Nakagawa K.

Ann Oncol. 2012 Nov;23(11):2931-6. doi: 10.1093/annonc/mds124. Epub 2012 Jul 5.

14.

[Therapeutic effects of crizotinib in EML4-ALK-positive patients with non-small-cell lung cancer].

Wu X, Li J.

Nan Fang Yi Ke Da Xue Xue Bao. 2015 May;35(5):753-7. Chinese.

PMID:
26018277
15.

Reply to C.G. Azzoli et al and C. Chouaid et al.

Leighl NB, Beca JM, Tsao MS, Hoch JS.

J Clin Oncol. 2014 Nov 1;32(31):3578-9. doi: 10.1200/JCO.2014.57.2552. Epub 2014 Sep 8. No abstract available.

16.

Reply to C.G. Azzoli et al and C. Chouaid et al.

Kelly RJ, Hillner BE, Smith T.

J Clin Oncol. 2014 Nov 1;32(31):3579-80. doi: 10.1200/JCO.2014.57.2560. Epub 2014 Sep 8. No abstract available.

17.

Crizotinib in the management of advanced-stage non-small-cell lung cancer.

Loong HH, Mok K, Leung LK, Mok TS.

Future Oncol. 2015;11(5):735-45. doi: 10.2217/fon.14.314. Review.

PMID:
25757678
18.

Crizotinib in the treatment of non--small-cell lung cancer.

Rothschild SI, Gautschi O.

Clin Lung Cancer. 2013 Sep;14(5):473-80. doi: 10.1016/j.cllc.2013.04.006. Epub 2013 Jun 20. Review.

PMID:
23790969
19.

Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.

Wu B, Chen H, Shen J, Ye M.

Clin Ther. 2011 Oct;33(10):1446-55. doi: 10.1016/j.clinthera.2011.09.016. Epub 2011 Oct 11.

PMID:
21992806
20.

Identification of atypical ATRNL1 insertion to EML4-ALK fusion gene in NSCLC.

Robesova B, Bajerova M, Hausnerova J, Skrickova J, Tomiskova M, Dvorakova D.

Lung Cancer. 2015 Mar;87(3):318-20. doi: 10.1016/j.lungcan.2015.01.002. Epub 2015 Jan 10.

PMID:
25601488
Items per page

Supplemental Content

Write to the Help Desk